NCT04977128

89Zr-labeled KN035 PET Imaging in Patients With PD-L1 Positive Solid Tumors

Safety Study of 89Zr-labeled KN035 PET Imaging in Patients With PD-L1 Positive Solid Tumors

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: Wuxi No. 4 People's Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is a single arm study to evaluate the safety and biodistribution of 89Zr-labeled KN035 (89Zr-KN035) PET Imaging in patients with PD-L1 positive solid tumors.

Detailed description

After being informed about the study and potential risks, all patients giving written informed consent will be evaluated to determine eligibility for study entry. Patients will receive an injection of 89Zr-KN035 and will undergo PET/CT scanning to determine uptake of 89Zr-KN035 in tumor lesions.

Conditions

• Solid Tumor, Adult

Interventions

Type	Name	Description
DRUG	89Zr-KN035	Patients will receive a tracer (10 mg, IV) dose of Zr-89 (2-3mCi) labelled KN035 (89Zr- KN035)

Timeline

• Start date: 2021-03-01
• Primary completion: 2022-03-31
• Completion: 2022-03-31
• First posted: 2021-07-26
• Last updated: 2021-07-26

Locations

1 site across 1 country: China